MX2024010102A - Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso. - Google Patents

Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso.

Info

Publication number
MX2024010102A
MX2024010102A MX2024010102A MX2024010102A MX2024010102A MX 2024010102 A MX2024010102 A MX 2024010102A MX 2024010102 A MX2024010102 A MX 2024010102A MX 2024010102 A MX2024010102 A MX 2024010102A MX 2024010102 A MX2024010102 A MX 2024010102A
Authority
MX
Mexico
Prior art keywords
beta
hydroxybutyrate
enantiomer
racemic mixture
methods
Prior art date
Application number
MX2024010102A
Other languages
English (en)
Inventor
Gary Millet
Original Assignee
Axcess Global Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65898649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2024010102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axcess Global Sciences Llc filed Critical Axcess Global Sciences Llc
Publication of MX2024010102A publication Critical patent/MX2024010102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/182—Diglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/192—Monoglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/194—Triglycerides
    • A23V2250/1946—Short-chain triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/71—Vitamin D
    • A23V2250/7106—Vitamin D3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones cetogénicas enriquecidas con el enantiómero S del beta-hidroxibutirato (BHB), que incluyen una mezcla no racémica de S-beta-hidroxibutirato y R-beta-hidroxibutirato, se formulan para controlar niveles de cuerpos de cetona en un sujeto. La mezcla no racémica de BHB se enriquece con el enantiómero S para modular el efecto de cuerpos de cetona en el sujeto y control de la velocidad en la cual se logra la cetosis. En algunos aspectos una composición para controlar el nivel de cuerpos de cetona en un sujeto contiene un portador dietéticamente o farmacéuticamente aceptable y una mezcla no racémica de S-beta-hidroxibutirato y R-beta-hidroxibutirato, en donde la mezcla no racémica comprende menos de aproximadamente 100% por equivalentes enantioméricos de enantiómero de S-beta-hidroxibutirato y más de aproximadamente 0% por equivalentes enantioméricos de enantiómero de R-beta-hidroxibutirato.
MX2024010102A 2017-12-19 2020-07-13 Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso. MX2024010102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607578P 2017-12-19 2017-12-19
US15/936,849 US10245243B1 (en) 2017-12-19 2018-03-27 Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use

Publications (1)

Publication Number Publication Date
MX2024010102A true MX2024010102A (es) 2024-08-30

Family

ID=65898649

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006386A MX2020006386A (es) 2017-12-19 2018-11-20 Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso.
MX2024010102A MX2024010102A (es) 2017-12-19 2020-07-13 Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020006386A MX2020006386A (es) 2017-12-19 2018-11-20 Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso.

Country Status (11)

Country Link
US (2) US10245243B1 (es)
EP (1) EP3727360A4 (es)
JP (1) JP7300449B2 (es)
CN (1) CN111655244A (es)
AU (1) AU2018390719C1 (es)
BR (1) BR112020012469A2 (es)
CA (1) CA3086517C (es)
MX (2) MX2020006386A (es)
MY (1) MY202787A (es)
SG (1) SG11202005546UA (es)
WO (1) WO2019125693A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11944598B2 (en) * 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) * 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN112516127A (zh) * 2019-09-17 2021-03-19 西安交通大学 羟基酪醇醋酸酯和β羟丁酸乙酯的联合使用在制备缓解脑疲劳的保健食品和药物中的应用
WO2021178547A1 (en) 2020-03-05 2021-09-10 Devon Price COMPOSITION OF (D)-β-HYDROXYBUTYRIC ACID, (D)-β-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
WO2022140130A1 (en) * 2020-12-22 2022-06-30 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
MX2023001899A (es) * 2021-03-24 2023-10-26 Axcess Global Sciences Llc Composiciones de acido beta-hidroxibutirico y metodos para suministro oral de cuerpos de cetona.
US11807600B2 (en) 2021-11-12 2023-11-07 Samuel J. Rozzoni Synthesis of novel ketone body analogs for use as a nutritional supplement
US20230346699A1 (en) * 2022-04-28 2023-11-02 Axcess Global Sciences, Llc Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications
WO2025201136A1 (zh) * 2024-03-25 2025-10-02 南京纽邦生物科技有限公司 组合物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2238149A (en) 1937-11-02 1941-04-15 Aeckerle Emil Process for improving the stability of hygroscopic substances
JPS63502274A (ja) 1985-12-18 1988-09-01 ビ−チ，リチヤ−ド　エル Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
US4997976A (en) * 1988-11-15 1991-03-05 Henri Brunengraber Use of 1,3-butanediol acetoacetate in parenteral oral nutrition
SE8803141L (sv) 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5116868A (en) 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
CA2283642C (en) 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
JPH1160434A (ja) 1997-08-12 1999-03-02 Kanebo Ltd 皮膚老化防止化粧料
US6380244B2 (en) 1998-07-22 2002-04-30 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
WO2000015216A1 (en) 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US6613356B1 (en) 2000-10-10 2003-09-02 Victor Vlahakos Weight loss medication and method
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US8158184B2 (en) 2004-03-08 2012-04-17 Bunge Oils, Inc. Structured lipid containing compositions and methods with health and nutrition promoting characteristics
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
EP1915144A4 (en) 2005-06-20 2009-08-19 Accera Inc METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008120778A1 (ja) * 2007-03-30 2008-10-09 Earthus, Inc. ケトン体生成促進剤組成物
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
WO2009073633A1 (en) 2007-11-30 2009-06-11 Alltranz Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
DK2240017T3 (da) * 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
KR102499654B1 (ko) * 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
US20170298339A1 (en) 2014-10-07 2017-10-19 Stc.Unm Engineered Stable Microorganism/Cell Communities
WO2016123229A1 (en) * 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
JP2017046688A (ja) * 2015-08-31 2017-03-09 株式会社みやぎヘルスイノベーション 体重増加抑制用飲料組成物
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2017208217A2 (en) 2016-06-01 2017-12-07 Aspi Ip Holder Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
WO2018089863A1 (en) 2016-11-11 2018-05-17 Bennes, Inc. Formulations for efficient delivery of cannabinoids
MX2020000734A (es) * 2017-07-21 2020-07-29 Buck Inst Res Aging Enantiómeros s de beta-hidroxibutirato y butanodiol, y métodos para usarlos.
US20190313682A1 (en) 2018-04-12 2019-10-17 Metabolic Recovery Systems, LLC Compositions and methods for supplementing the diet

Also Published As

Publication number Publication date
US10596128B2 (en) 2020-03-24
AU2018390719C1 (en) 2023-08-17
EP3727360A1 (en) 2020-10-28
MX2020006386A (es) 2020-10-28
AU2018390719B2 (en) 2022-12-01
CN111655244A (zh) 2020-09-11
US20190183820A1 (en) 2019-06-20
WO2019125693A1 (en) 2019-06-27
AU2018390719A1 (en) 2020-07-02
EP3727360A4 (en) 2021-08-25
US10245243B1 (en) 2019-04-02
BR112020012469A2 (pt) 2020-11-24
SG11202005546UA (en) 2020-07-29
MY202787A (en) 2024-05-21
JP7300449B2 (ja) 2023-06-29
CA3086517C (en) 2023-08-01
CA3086517A1 (en) 2019-06-27
JP2021506294A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
MX2024010102A (es) Compuestos de beta-hidroxibutirato no racemicos y composiciones enriquecidas con enantiomero s y metodos de uso.
MY196526A (en) Non-Racemic Beta-Hydroxybutyrate Compounds and Compositions Enriched With The R-Enantiomer And Methods Of Use
Nikolić et al. Chemical composition, antimicrobial, and cytotoxic properties of five Lamiaceae essential oils
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
WO2015168635A3 (en) Compositions and methods for modulating complement factor b expression
MX2022005380A (es) Composiciones que comprenden colina.
CL2008002910A1 (es) Composicion base para un desodorante tipo barra que comprende entre 20 y 70% en peso de propilenglicol, 5 a 60% de glicerina, 10 a 35% de agua y un agente espesante; metodo para inhibir el crecimiento bacteriano.
BR112018010024A8 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
BR112018011216A2 (pt) métodos para inibir a conversão de colina em trimetilamina (tma)
BR112017014991A2 (pt) trilho
BR112019006932A2 (pt) composições antimicrobianas
MX2017015247A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
AR100453A1 (es) Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física
CO2022008308A2 (es) Tieniloxazolonas y análogos
CL2016003155A1 (es) Composiciones de cuidado bucal
AR053691A1 (es) Agentes endoparasiticidas
EP3923924A4 (en) NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND COMPOSITIONS ENRICHED WITH THE R-ENANTIOMER, AND METHODS OF USE THEREOF
ECSP21008630A (es) Planta brassica oleracea rica en s-metilmetionina
BR112022005045A2 (pt) Forma de dosagem, uso e kit de (s)-bupropiona que é pelo menos 95% enantiomericamente pura
MX2017005745A (es) Composiciones antisarro para el cuidado bucal que proporcionan la prevencion de la cristalizacion.
AR104877A1 (es) Composiciones y métodos para la administración de un polinucleótido en una planta
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
MX2017007269A (es) Estabilidad del peroxido.